Skip to content
Inciteful Med

Treatment Strategy: ERT vs SRT

Last updated:

For Gaucher disease, the main treatment choice is between Enzyme Replacement Therapy (ERT), delivered via bi-weekly IV infusions to replace the missing enzyme, and Substrate Reduction Therapy (SRT), a daily oral pill that reduces waste production. ERT is generally used for children and pregnancy, while SRT requires genetic testing for eligibility.

Key Takeaways

  • • ERT replaces the missing enzyme via IV infusions, while SRT reduces waste production via oral pills.
  • • ERT is the gold standard for safety in children and during pregnancy.
  • • Patients must undergo CYP2D6 genetic testing to determine if they are eligible for the SRT drug eliglustat.
  • • Miglustat is a second-line oral option often associated with significant gastrointestinal side effects.

Once diagnosed, the next step is choosing a treatment strategy. For most patients, there are two primary paths: Enzyme Replacement Therapy (ERT), which has been the “gold standard” for decades, and Substrate Reduction Therapy (SRT), a newer oral alternative [1][2].

The goal of both treatments is the same: to stop the buildup of fatty waste in your organs and bones [1].

Enzyme Replacement Therapy (ERT)

ERT works by providing your body with the enzyme it is missing (glucocerebrosidase). Because the enzyme is a large protein, it cannot be taken as a pill; it must be delivered directly into the bloodstream [1].

  • Administration: Typically given as an intravenous (IV) infusion every two weeks. Infusions usually last 1–2 hours and can often be done at home after an initial period in a clinic [3].
  • Approved Medications:
    • Imiglucerase (Cerezyme): The longest-studied ERT with a decades-long safety record [4].
    • Velaglucerase alfa (VPRIV): Made using human cell lines; has similar effectiveness to imiglucerase [5].
    • Taliglucerase alfa (Elelyso): Derived from carrot cells, offering another effective option for patients [6].
  • Pros/Cons: ERT is considered very safe and is the only treatment approved for children [7]. The main downside is the need for regular needles and infusion appointments.

Substrate Reduction Therapy (SRT)

Instead of replacing the missing enzyme, SRT works by “turning down the faucet.” It slows the production of the fatty substance (glucosylceramide) so that your low levels of natural enzyme can keep up with the “recycling” [2].

  • Eliglustat (Cerdelga): This is the primary first-line SRT for adults. It is taken as a pill once or twice a day [8].
    • The CYP2D6 Test: Before starting Cerdelga, you must have a blood test to check your CYP2D6 metabolism [9]. This gene determines how fast your body processes the drug. If you are an “ultra-rapid metabolizer,” the drug won’t work; if you are a “poor metabolizer,” you need a much lower dose [9][10].
  • Miglustat (Zavesca): An older SRT usually reserved for patients who cannot use ERT or eliglustat.
    • Side Effects: It is known for causing significant gastrointestinal issues (like diarrhea and gas) and, in some cases, hand tremors or numbness [11][12].
  • Pros/Cons: SRT offers the convenience of a pill and freedom from infusions [2]. However, it is not for everyone and is generally not used in children or during pregnancy [13].

Special Considerations

Pregnancy and Breastfeeding

If you are planning a family, your treatment choice is vital.

  • ERT: Generally considered safe and is often continued throughout pregnancy to prevent Gaucher-related complications for the mother and baby [5][7].
  • SRT: Medications like Cerdelga and Zavesca are not recommended during pregnancy [13][14]. Women on these drugs are usually advised to switch to ERT well before conceiving [13].

The Future: Gene Therapy

While ERT and SRT are lifelong treatments, researchers are working on gene therapy [15]. This involves using a modified virus to deliver a healthy copy of the GBA1 gene into your cells, potentially allowing the body to produce its own enzyme permanently [16][17]. Clinical trials are currently underway [15].

Feature Enzyme Replacement (ERT) Eliglustat (SRT) Miglustat (SRT)
Form IV Infusion (every 2 weeks) Daily Pill Daily Pill
Best For Children & Adults; Pregnancy Adults (Extensive Metabolizers) Adults (2nd Line Only)
Side Effects Rare infusion reactions Few (Headache, nausea) Significant (Diarrhea, tremor)
Key Test Enzyme Assay (for diagnosis) CYP2D6 Genetic Test None specific

Frequently Asked Questions

What is the difference between ERT and SRT for Gaucher disease?
ERT works by delivering the missing enzyme (glucocerebrosidase) directly into the bloodstream through an IV infusion every two weeks. SRT works differently by using a daily pill to slow down the body's production of the fatty substance that builds up, allowing the remaining natural enzyme to manage the load.
Do I need a specific test before starting Cerdelga?
Before taking the SRT drug eliglustat (Cerdelga), you must have a CYP2D6 blood test. This genetic test checks how fast your body metabolizes the drug to determine if it will work for you and what the correct dosage should be.
Is it safe to take SRT pills while pregnant?
No, oral SRT medications like Cerdelga and Zavesca are not recommended during pregnancy. Women planning to conceive are typically advised to switch to ERT, which has a strong safety record for both mother and baby.
What are the side effects of Miglustat?
Miglustat (Zavesca) is an older oral medication often reserved for patients who cannot use other treatments. It is known for causing significant digestive side effects like diarrhea and gas, as well as potential hand tremors or numbness.
Which treatment is better for children?
ERT is currently the only treatment approved for children with Gaucher disease. SRT is generally not used in pediatric patients.

Questions for Your Doctor

  • • Based on my lifestyle and disease severity, am I a better candidate for intravenous ERT or oral SRT?
  • • Can we order a CYP2D6 genotype test to see if I am eligible for Cerdelga (eliglustat)?
  • • If I choose ERT, which of the three brands—Cerezyme, VPRIV, or Elelyso—is the best fit for me?
  • • What is the plan for my treatment if I decide to become pregnant in the next few years?
  • • If I start on Zavesca (miglustat), how should I manage the potential gastrointestinal side effects?

Questions for You

  • • How do I feel about receiving an IV infusion every two weeks versus taking a pill every day?
  • • Am I able to strictly follow a daily medication schedule, or would I prefer the 'set it and forget it' nature of a bi-weekly clinic visit?
  • • Is the freedom to travel or work without infusion appointments a high priority for me?
  • • Am I comfortable with the trade-off of potentially more side effects (with oral SRT) versus the long-proven safety of ERT?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [Gaucher disease: A review].

    Nguyen Y, Stirnemann J, Belmatoug N

    La Revue de medecine interne 2019; (40(5)):313-322 doi:10.1016/j.revmed.2018.11.012.

    PMID: 30638965
  2. 2

    Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.

    Belmatoug N, Di Rocco M, Fraga C, et al.

    European journal of internal medicine 2017; (37()):25-32 doi:10.1016/j.ejim.2016.07.011.

    PMID: 27522145
  3. 3

    Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.

    Zimran A, Elstein D, Gonzalez DE, et al.

    Blood cells, molecules & diseases 2018; (68()):153-159 doi:10.1016/j.bcmd.2016.10.007.

    PMID: 27839979
  4. 4

    Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.

    Weinreb NJ, Camelo JS, Charrow J, et al.

    Molecular genetics and metabolism 2021; (132(2)):100-111 doi:10.1016/j.ymgme.2020.12.295.

    PMID: 33485799
  5. 5

    Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey.

    Lau H, Belmatoug N, Deegan P, et al.

    Blood cells, molecules & diseases 2018; (68()):226-231 doi:10.1016/j.bcmd.2016.10.003.

    PMID: 27839985
  6. 6

    Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.

    Zimran A, Durán G, Mehta A, et al.

    American journal of hematology 2016; (91(7)):656-60 doi:10.1002/ajh.24369.

    PMID: 27174694
  7. 7

    Safety and efficacy of velaglucerase alfa replacement therapy for patients with type 1 Gaucher disease.

    Elstein D, Zimran A

    Expert review of endocrinology & metabolism 2013; (8(4)):333-339 doi:10.1586/17446651.2013.811871.

    PMID: 30736148
  8. 8

    Eliglustat: A Review in Gaucher Disease Type 1.

    Scott LJ

    Drugs 2015; (75(14)):1669-78 doi:10.1007/s40265-015-0468-9.

    PMID: 26384672
  9. 9

    Type 1 Gaucher disease (CYP2D6-eliglustat).

    Becquemont L

    Therapie 2017; (72(2)):323-326 doi:10.1016/j.therap.2016.09.019.

    PMID: 28242126
  10. 10

    Physiologically-Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug-Drug Interactions.

    Sahasrabudhe SA, Cheng S, Al-Kofahi M, et al.

    Clinical pharmacology and therapeutics 2022; (112(6)):1254-1263 doi:10.1002/cpt.2738.

    PMID: 36056771
  11. 11

    Evaluation of the safety and efficacy of miglustat for the treatment of Chinese patients with Niemann-Pick disease type C: A prospective, open-label, single-arm, phase IV trial.

    Zhang H, Xiong H, Wei C, et al.

    Intractable & rare diseases research 2024; (13(4)):227-235 doi:10.5582/irdr.2024.01056.

    PMID: 39628618
  12. 12

    A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat.

    Remenova T, Morand O, Amato D, et al.

    Orphanet journal of rare diseases 2015; (10()):81 doi:10.1186/s13023-015-0297-7.

    PMID: 26084276
  13. 13

    Recommendations for oral treatment for adult patients with type 1 Gaucher disease.

    Torralba-Cabeza MÁ, Morado-Arias M, Pijierro-Amador A, et al.

    Revista clinica espanola 2022; (222(9)):529-542 doi:10.1016/j.rceng.2022.02.008.

    PMID: 35676195
  14. 14

    Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials.

    Lukina E, Balwani M, Belmatoug N, et al.

    JIMD reports 2021; (57(1)):76-84 doi:10.1002/jmd2.12172.

    PMID: 33473343
  15. 15

    Understanding patient and parent/caregiver perceptions on gene therapy in Gaucher disease: an international survey.

    Collin-Histed T, Rosenberg A, Hopman N, Pacey J

    Orphanet journal of rare diseases 2023; (18(1)):5 doi:10.1186/s13023-022-02576-3.

    PMID: 36611195
  16. 16

    Gene Therapy of Sphingolipid Metabolic Disorders.

    Shaimardanova AA, Solovyeva VV, Issa SS, Rizvanov AA

    International journal of molecular sciences 2023; (24(4)) doi:10.3390/ijms24043627.

    PMID: 36835039
  17. 17

    Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes.

    Massaro G, Hughes MP, Whaler SM, et al.

    Human molecular genetics 2020; (29(12)):1933-1949 doi:10.1093/hmg/ddz317.

    PMID: 31919491

This guide compares Gaucher disease treatment options for educational purposes. Always consult your hematologist or geneticist to determine the best therapy for your specific medical needs.

Stay up to date

Get notified when new research about Gaucher Disease is published.

No spam. Unsubscribe anytime.